Booth #1934

San Diego, CA, USA

Join our scientific sessions and poster presentations at this year’s SOT, featuring the latest GARD^® data and case studies generated in collaboration with industry leaders.

Meet us at booth #1934 and discuss your specific testing needs with our scientific team – We help you design testing strategies tailored to your substances and regulatory goals: from “2 out of 3” defined approaches according to OECD 497, to exploratory studies supporting product development.

Exhibitor-Hosted Session

Advancing NAMs for Skin and Respiratory Sensitization: UVCBs, Natural Extracts and Medical Devices

New GARD^® advances in respiratory sensitization,  ISO 10993-10 compliance for medical devices, quantitative potency assessment, and difficult-to-test samples

Room 23A | Tue, 24 March | 10:45 am-11:45 am

1. Introduction to GARD^® technology for skin and respiratory sensitization testing

🎤Andy Forreryd, PhD |  Scientific Liaison, SenzaGen

2. Evaluating sensitization potential of medical devices in vitro using GARD^®skin assay: a practical in vitro sensitization case study in medical device development

🎤Yizhong Liu, PhD, DABT | Senior Scientist and Toxicologist, Johnson & Johnson MedTech

3. GARD^®air for the prediction of respiratory sensitization for substances of regulatory concern

🎤Emily Reinke, PhD, DABT | Principal Toxicologist, GDIT (contractor supporting NICEATM)

4. Respiratory sensitization hazard identification: navigating assay exploration for biocatalytic enzymes

🎤Joshua Vaughan, PhD, DABT | Principal Scientist, Merck

Speaking in Symposium Sessions

In Vitro Testing for Skin Sensitization of Mixtures: Where Science Stands Today

Room 7B | Wed, 25 March | 8:00 am-10:45 am

Chairs: The Honest Company, Edgewell Personal Care | SenzaGen: Dr Tim Lindberg | SenzaGen: Dr Tim Lindberg

Human Health Risk Assessments of Biopesticides: Evaluating Safety for Agricultural Use

Ballroom 6F | Wed, 25 March | 1:30 PM-4:15 PM

Chairs: Bayer Crop Science, Corteva Agriscience | SenzaGen: Dr Andy Forreryd

Posters

🎫 K764 | #5200 | Case study: Fragrance formulations – Jointly with Coty

Improving the safety profiles of fragrance formulations: modulating the skin sensitization potential to reduce or eliminate the risk of allergic skin reactions

🎫 K762 | #5198 | Case study: 2o3 DA applied to UVCBs – Jointly with ExxonMobil

Applying the “2 out of 3” Defined Approach (OECD 497) to assess skin sensitization potential of UVCBs using the GARD^®skin and EpiSensA assays

🎫 K759 | #5195 | Case study: NESIL prediction for OTC drugs – Jointly with Haleon

Predicting NESIL using New Approach Methodologies: a case study on quantitative skin sensitization assessment of topical over-the-counter pharmaceutical candidates

🎫B175 | #3072 | Medical Device ISO 10993-10

In vitro sensitization assessment of medical device extracts: Prevalidation results of GARD^®skin Medical Device for potential inclusion in ISO 10993-10

🎫G546 | #3403 | New alternative gene expression platform for GARD^®

RNA-seq can be used for gene expression quantification in the GARD^®skin method for assessment of skin sensitizers